Verve therapeutics to participate in the guggenheim securities smid cap biotech conference

Boston, jan. 29, 2025 (globe newswire) -- verve therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that sekar kathiresan, m.d., co-founder and chief executive officer, will participate in a fireside chat at the guggenheim securities smid cap biotech conference on wednesday, february 5, 2025 at 9 a.m. et in new york.
SMID Ratings Summary
SMID Quant Ranking